- The interim report for 1 January - 30 September 2023 will be published on 26 October 2023
- The Year-end report for 1 January - 31 December 2023 will be published on 2 February 2024
- The interim report for 1 January - 31 March 2024 will be published on 24 April 2024
- The Annual General Meeting (AGM) of AddLife AB (publ) will be held on 8 May 2024, 4 PM, Stockholm
Capital Markets Day
AddLife invites analysts, professional investors and media to Capital Markets Day Friday 15 September 2023 08:30-12:00 a.m at Studio Puck, Kommendörsgatan 24, Stockholm. The presentation will be webcast live and be posted on AddLife´s Youtube channel.
For further information, please contact:
Fredrik Dalborg, President and CEO, +46 70 516 09 01
Christina Rubenhag, CFO, +46 70 546 72 22
ADDLIFE IN BRIEF
AddLife is an independent provider in Life Science that offers high-quality products, services and advice to both the private and public sector in Europe. The group is divided into two business areas: Labtech and Medtech. The group comprises some 85 operating subsidiaries that provide equipment, instruments, medical devices and reagents, as well as advice and technical support to customers primarily in healthcare, research and academia, along with the food and pharmaceutical industries.
This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7:45 a.m. CET on July 14, 2023.
AddLife AB (publ), Box 3145, Brunkebergstorg 5, SE-103 62 Stockholm. firstname.lastname@example.org, www.add.life, org.nr. 556995-8126